La vignette diagnostique de l'etudiant. Le spectre des toxidermies.

Adult; Anti-Bacterial Agents/adverse effects/therapeutic use; Drug Eruptions/classification/diagnosis/epidemiology/prevention & control; Fatal Outcome; Female; Humans; Severity of Illness Index; Tracheitis/drug therapy

Abstract :

[en] Drug eruptions are frequently encountered and they represent "diseases of medical progress". They are expected in about 2% of treated patients. Their putative diagnosis is based on a set of imputability factors. Several distinct drug-induced skin disorders are identified. They are initially recognized from personal experience, but the implication to a specific drug derives from the collective experience of published evidence. Their histopathological aspect is often evocative or demonstrative for the nature of the dermatosis. Some drug eruptions follow an indolent course, while others are life-threatening.

Disciplines :

Dermatology

Author, co-author :

Hermanns-Lê, Trinh ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

La vignette diagnostique de l'etudiant. Le spectre des toxidermies.

Alternative titles :

[en] The spectrum of drug eruptions

Publication date :

2013

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

44-50

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 May 2013

Statistics

Number of views

138 (4 by ULiège)

Number of downloads

516 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Paquet P, Flagothier C, Piérard-Franchimont C, et al. - Les toxidermies paraxystiques graves. Rev Med Liège, 2004, 59, 286-282
Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. - Imputabilité médicamenteuse dans les iatrogénies cutanées. Rev Med Liège, 2011, 66, 474-477.
Hagen JW, Magro CM, Crowson AN. - Emerging adverse cutaneous drug reactions. Dermatol Clin, 2012, 30, 695-730.
Khan DA. - Cutaneous drug reactions. J Allergy Clin Immunol, 2012, 130, 1225-1225.
Mockenhaupt M. - Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy, 2012, 97, 1-17.
Piérard-Franchimont C, Quatresooz P, Reginster PA, et al. - Revisiting cutaneous adverse reactions to pemetrexed. Oncol Letters, 2011, 2, 769-772.
Piérard-Franchimont C, Piérard GE. - L'iatrogénie psoriasique. Rev Med Liège, 2012, 67, 139-142.
Wei CY, Ko TM, Shen CY, et al. - A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet, 2012, 27, 132-141.
Yip VL, Marson AG, Jorgensen AL. - HLA genotype and carbamazepine-induced cutaneous adverse drug reactions : a systematic review. Clin Pharmacol Ther, 2012, 92, 757-765.
Piérard GE, Piérard-Franchimont C. - Des herbes pour la dermatite atopique: phytothérapie de l'apprenti sorcier ou mascarade trompeuse et couplabe? Rev Med Liège, 1999, 54, 539-540.
Glatz M, Hofbauer GF. - Phototoxic and photoallergic cutaneous drug reactions. Chem Immunol Allergy, 2012, 97, 167-179.
Ravnan MC, Matalka MS. - Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther, 2012, 34, 1474-1486.
Lamchahab F, Baeck M. - Occupatonally induced fixed drug eruption caused by a non-steroidal antiinflammatory agent. Contact Dermatitis, 2012, 67, 176-177.
Bavbek S, Yilmaz I, Sözener ZC. - Fixed drug eruption caused by ornidazole and fluconazole but not isoconazole, itraconazole, ketoconazole and metronidazole. J Dermatol, 2012, Epub Oct 30.
Shiohara T, Mizukawa Y. - Fixed drug eruption: the dark side of activation of intraepidermal CD8+ T cells uniquely specialized to mediate protective immunity. Chem Immunol Allergy, 2012, 97, 106-121.
Sokumbi O, Wetter DA. - Clinical features, diagnosis, and treatment of erythema multiforme : a review for the practicing dermatologist. Int J Dermatol, 2012, 51, 889-902.
Paquet P, Piérard GE. - New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical considerations, pathobiology and targeted treatments revisited. Drug Saf, 2010, 33, 189-212.
Piérard GE, Paquet P. - Facing up to toxic epidermal necrolysis. Expert Opin Pharmacother, 2010, 11, 2443-2446.
Paquet P, Delvenne P, Piérard GE. - Drug interactions with normal and TEN epidermal keratinocytes. Curr Drug Saf, sous presse.
Paquet P, Meuwis MA, Mazzuccheli, et al. - Proteomic kinetic analysis of blister fluid and serum in a patient with drug-induced toxic epidermal necrolysis. A comparison with skin immunohistochemistry. Curr Drug Saf, sous presse.
Jennes S, Piérard GE, Paquet P. - Deciphering supportive treatment strategies for toxic epidermal necrolysis. Curr Drug Saf, sous presse.
Harr T, French LE. - Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy, 2012, 97, 149-166.
Paquet P, Vandenbossche G, Nikkels AF, et al. - Pustulose exanthématique aiguë généralisée due à un agent de contraste iodé pour radiodiagnostic. Rev Med Liège, 2009, 64, 601-605.
Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al. - Toxic epidermal necrolysis, DRESS, AGEP : do overlap cases exist ? Orphanet J Rare Dis, 2012, 7, 72.
Bourguignon R, Piérard-Franchimont C, Paquet P, et al. - Syndrome DRESS à la sulfasalazine. Rev Med Liège, 2006, 61, 643-648.
Miller Quidley A, Bookstaver PB, Gainey AB, et al. - Fatal clindamycin-induced drug rash with eosinophil and systemic symptoms (DRESS) syndrome. Parmacotherapy, 2012, Nov 16.
Walsh S, Diaz-Cano S, Higgins E, et al. - Drug reaction with eosinophilia and systemic symptoms (DRESS) : is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol, 2012, Epub Oct 3.
Barbaud A, Collet E, Milpied B, et al. - A multicenter study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol, 2012, Epub Nov 8.